PWM
TGTX icon

Perigon Wealth Management’s TG Therapeutics TGTX Stock Holding History

Perigon Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,000
Closed -$145K – 254
2019
Q1 		$145K Buy
+18,000
New +$97.3K 0.03% 217

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perigon Wealth Management's TGTX Position: Q2 2019 in Review

Perigon Wealth Management sold out of TG Therapeutics (TGTX) in Q2 2019, closing a stake of 18,000 shares — an estimated $145K sold.

Perigon Wealth Management first reported a position in TGTX in Q1 2019 and held it in 1 quarter. The position peaked at $145K in Q1 2019. 116 funds tracked by Wall St. Rank hold TGTX as of Q2 2019.

  • Perigon Wealth Management reported no remaining TG Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Perigon Wealth Management sold 18,000 TG Therapeutics shares in Q2 2019, an estimated $145K.
  • Perigon Wealth Management first reported a position in TG Therapeutics in Q1 2019 and held it in 1 quarter.
  • Perigon Wealth Management's TG Therapeutics position peaked at $145K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2019.

Based on Perigon Wealth Management's 13F filing for Q2 2019, filed 5 Aug 2019.